---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic impact of diagnostic testing"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Economic impact of diagnostic testing. Topics: Medicare diagnostic testing requirement for CPAP coverage; Sleep test documentation required for prior authorization of tirzepatide for obstructive sleep apnea; Share of U.S. diagnosis and treatment spending attributed to testing and office visits, 2015; Home versus laboratory diagnostic pathway: payer and provider costs in the HomePAP trial; 5 further topics. 9 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Medicare diagnostic testing requirement for CPAP coverage

> “The AHI and/or RDI may be measured by polysomnography (PSG) in a facility-based sleep study laboratory, or by a Type II home sleep test (HST) monitor, a Type III HST monitor, or a Type IV HST monitor measuring at least 3 channels.”
> “A positive diagnosis of OSA for the coverage of CPAP must include a clinical evaluation and a positive:”

Source: [CMS National Coverage Determination 240.4 (2008)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=226)

<a id="topic-2.2.1.8.4-2"></a>

### Sleep test documentation required for prior authorization of tirzepatide for obstructive sleep apnea

> “The patient has an established diagnosis of moderate to severe OSA with an apnea-hypopnea index (AHI) of at least 15 events per hour on polysomnography (PSG) or home sleep apnea test (HSAT) with a technically adequate device.”

Source: [Aetna Zepbound prior authorization policy (2026)](https://www.aetna.com/products/rxnonmedicare/data/2026/Zepbound%20PA%20with%20Limit%206192-C%2008-2026%20v3.html)

<a id="topic-2.2.1.8.4-3"></a>

### Share of U.S. diagnosis and treatment spending attributed to testing and office visits, 2015

> “Frost & Sullivan estimates that the cost for diagnosing and treating OSA in the United States in 2015 was approximately $12.4 billion. Approximately 7% of these costs are from physician office visits and testing which are necessary for diagnosis and ongoing management.”
> “costs average $2,105 per year for testing, appointments, treatment devices and surgery if necessary.”
> “Diagnosis can involve multiple referral appointments and an overnight sleep test, which can be difficult for some individuals. Home sleep apnea testing, although less expensive and more convenient, lacks the sensitivity to rule out a sleep apnea diagnosis because it does not generally record sleep and wakefulness.”

Source: [Frost & Sullivan (2016)](https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf)

<a id="topic-2.2.1.8.4-4"></a>

### Home versus laboratory diagnostic pathway: payer and provider costs in the HomePAP trial

> “From the payer perspective, per subject costs for the laboratory-based pathway were $1,840 (95% confidence interval [CI] $1,660, $2,015) compared to $1,575 (95% CI $1,439, $1,716) for the home-based pathway under the base case. Costs were $264 (95% CI $39, $496, P = 0.02) in favor of the home arm.”
> “For payers, a home-based diagnostic pathway for obstructive sleep apnea with robust patient support incurs fewer costs than a laboratory-based pathway. For providers, costs are comparable if not higher, resulting in a negative operating margin.”

Source: [Kim et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481018/)

<a id="topic-2.2.1.8.4-5"></a>

### Home versus laboratory diagnostic pathway: clinical outcomes in the HomePAP trial

> “A home-based strategy for diagnosis and treatment compared with in-laboratory PSG was not inferior in terms of acceptance, adherence, time to treatment, and functional improvements.”

Source: [Rosen et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3353048/)

<a id="topic-2.2.1.8.4-6"></a>

### Home versus laboratory diagnostic pathway: functional outcome in veterans

> “Functional outcome and treatment adherence in patients evaluated according to a home testing algorithm is not clinically inferior to that in patients receiving standard in-laboratory polysomnography.”

Source: [Kuna et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21471093/)

<a id="topic-2.2.1.8.4-7"></a>

### Cost-effectiveness of diagnostic strategies with CPAP in a U.S. lifetime model

> “Over the lifetime horizon in a population with 50% prevalence of OSA, full-night polysomnography in conjunction with CPAP therapy is the most economically efficient strategy at any willingness-to-pay greater than $17,131 per-QALY gained because it dominates all other strategies in comparative analysis.”

Source: [Pietzsch et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3098944/)

<a id="topic-2.2.1.8.4-8"></a>

### Cost-utility of polysomnography, home testing, and empirical CPAP

> “The incremental charges for polysomnography over home study or no testing were about $13,400 and $9200, respectively, per quality-adjusted life-year gained during this period.”

Source: [Chervin et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10075617/)

<a id="topic-2.2.1.8.4-9"></a>

### Systematic review of economic evaluations of diagnostic strategies

> “Twenty-nine studies were included. Fifteen studies included an economic evaluation alongside a clinical trial and 14 studies were model-based economic analyses.”
> “Substantial methodological heterogeneity was identified across studies, including variation in diagnostic thresholds and scoring criteria used, model structures and assumptions regarding treatment adherence.”

Source: [Osman et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13721662/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
